Home/Genewity/Ir. Bart Bergstein

IB

Ir. Bart Bergstein

Chief Financial Officer

Therapeutic Areas

Rare Pediatric Diseases Immunodeficiency Genetic Disorders

Genewity Pipeline

Drug	Indication	Phase
RAG1-SCID	Recombinase 1-Activating Gene 1 Severe Combined Immunodeficiency	Clinical

Leadership Team at Genewity

Arno Bisschop, MD, PhD, MSc

Chief Executive Officer

Willem-Jan Krebber, MBiotech, MSc

Chief Development Officer

Max Renes, MPhil, MSc

Chief Business Officer

Sijmen de Vries, MD, MBA

Non-executive Board Chair

View full Genewity profile